The average development timeline from first preclinical in vivo data to regulatory approval for a novel peptide therapeutic is 8–15 years, with an estimated clinical development success rate of approximately 14%, considerably lower than small molecule success rates (~24%). These barriers shape how a preclinical study has to be designed when its data are meant to support later clinical development.
What an IND application requires
The GLP toxicology requirement alone typically adds 12–18 months to preclinical timelines. Researchers publishing non-GLP pharmacology data, the majority of academic peptide literature, are producing data relevant to mechanism but insufficient for IND filing.
Barriers that stop peptides before an IND
The primary technical barriers preventing preclinical peptides from advancing to clinical trials include:
- Oral bioavailability: Most peptides ≥3 kDa have <1% oral bioavailability due to gastrointestinal proteolysis and poor epithelial permeability. GLP-1R agonists achieved meaningful oral bioavailability through fatty acid conjugation and SNAC co-formulation. Emerging approaches include permeation enhancers, cyclization, N-methylation, and PEGylation.
- Serum half-life: Unmodified linear peptides have plasma half-lives of minutes to hours. Albumin binding, PEGylation, and cyclization extend half-life to days.
- Immunogenicity: Novel peptide sequences can elicit anti-drug antibody (ADA) responses that neutralize activity. ADA incidence must be monitored in all clinical phases; T-cell epitope mapping and ex vivo human PBMC assays are standard preclinical requirements.
Programmes in clinical stages
The most advanced translational programs beyond established GLP-1/GIP agonists include: GLP-1/GIP/GCG triple agonism (Retatrutide Phase 3 TRIUMPH); oral semaglutide (Rybelsus approved, driving oral formulation interest); peptide-drug conjugates (PDCs) for tumor targeting; and mitochondria-targeting peptides (SS-31/Elamipretide, Phase 2 in mitochondrial myopathy and heart failure, registered on ClinicalTrials.gov). Neuropeptide programs (Selank, Semax, Cerebrolysin) remain predominantly in Russian/Eastern European clinical databases without ICH-harmonized Phase 3 programs.
Documentation that keeps data usable
Preclinical researchers who intend their data to support eventual translational development should: document compound characterization (lot, CoA, purity, identity) to IND-submission standard; use validated biomarkers with established clinical correlates; employ GLP-compliant study designs for pivotal experiments; and pre-specify statistical analysis plans. These compounds are for research and laboratory use only. Not for unsupervised human consumption.